

Journal of Commercial Biotechnology

**Biotecnología
Industrial
007**

¥


Rs

\$

€

INTI-Extensión y Desarrollo
División Biblioteca

29 MAR 2010



Contents

Editorial

- Time for a new business model?
Yali Friedman 1

Commentaries

- Why data exclusivity is the new patent protection
Peter J. Pitts 3
- Follow-on biologic drug competition – No need for new marketing exclusivities
Michael S. Wroblewski and Elizabeth A. Jex 5

Original Articles

- Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb
Nigel Borshell and Adrian Dawkes 8
- Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firms
Mark J. Ahn, Michael Meeks, Sally Davenport and Rebecca Bednarek 17
- Intellectual property landscape and patenting opportunity in biofuels
Ramasamy Mannan 33
- Challenges and opportunities in the licensing of renewable technologies
Meredith Lloyd-Evans, Mike Gilbert and Ilian P. Iliev 47
- Ethiopia: Biotechnology for development
Desta Berhe Sbhatu 53
- Innovation and commercialisation in the stem cell industries in Australia: State strategies and other opportunities to build a competitive position in the global stem cell economy
Olivia Harvey 72

Book Reviews

- Health-care investing: Profiting from the new world of pharma, biotech and health-care services
Reviewed by Frank LaSaracina 84
- Aging, Biotechnology, and the Future
Reviewed by Harley King 86

Intellectual Property Management

- Using IP audits to optimize IP assets
James G. Cullem 88